spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  von Willebrand Disease 

 HSMN NewsFeed - 21 Feb 2023
Hemab Therapeutics Announces $135M Series B Financing to Advance First Prophylactic Treatments for Underserved Bleeding and Thrombotic Disorders
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 27 Dec 2016
Shire Announces FDA Approval of Adynovate(R) for use in Children and Surgical Settings
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Aug 2016
Shire Announces FDA Approval of adynovate with BAXJECT III Reconstitution System
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Sep 2015
FDA Approves Octapharma’s NUWIQ for the Treatment of Adults and Children with Hemophilia
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Jul 2015
U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Feb 2015
FDA Approves New Dosing Option for CSL Behring's Hizentra(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Sep 2013
CSL Behring Announces FDA Approval of a 10 g (50 mL) Vial Size for Hizentra(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Feb 2013
CSL Behring Receives FDA Approval to Expand the Indication for Corifact(R)
Biopharmaceuticals Surgery FDA
 HSMN NewsFeed - 4 Oct 2012
Study Supports Efficacy, Safety of Hizentra(R) in Japanese Patients with Primary Immunodeficiency Disease
Biopharmaceuticals
 HSMN NewsFeed - 27 Jun 2012
PRIMA Study Shows Treatment with Privigen(R) Improved Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Biopharmaceuticals
 HSMN NewsFeed - 15 Mar 2012
CSL Behring Announces First Patient Treated in Phase III Study of Fibrinogen Concentrate (Human)(FCH) to Control Bleeding During Aortic Aneurysm Surgery
Biopharmaceuticals Surgery
 HSMN NewsFeed - 3 Jan 2012
CSL Behring Receives FDA Approval of Expanded Label on Berinert(R) for Self-administration and Treatment of Acute Laryngeal Attacks of Hereditary Angioedema
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 27 Jan 2011
CSL Behring Receives National Marketing Authorization of Berinert(R) in Israel
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 Dec 2010
Octapharma USA Focuses on Urgent Surgeries as FDA Approves octaplex(R) for Fast Track Development
Biopharmaceuticals Surgery FDA
 HSMN NewsFeed - 7 Oct 2010
Privigen(R) Demonstrates Efficacy and Tolerability Among Patients With Various Immunodeficiencies, Data Show
Biopharmaceuticals
 HSMN NewsFeed - 7 Oct 2010
Data Support Hizentra(R) Efficacy, Safety After Dose-Equivalent Switch in Adult and Pediatric Patients with Primary Immunodeficiency
Biopharmaceuticals
 HSMN NewsFeed - 7 Oct 2010
Study Demonstrates Safety and Efficacy of Subcutaneous Vivaglobin(R) as First-Line Therapy for Primary Immunodeficiency
Biopharmaceuticals
 HSMN NewsFeed - 13 Jan 2010
Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Dec 2009
Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Oct 2009
CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Mar 2009
CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jan 2009
CSL Behring Receives FDA Approval of RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Mar 2008
CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
Biopharmaceuticals
 HSMN NewsFeed - 19 Dec 2007
CSL Behring Expands Into Middle East Market with Haemate(R) P
Biopharmaceuticals
 HSMN NewsFeed - 26 Nov 2007
CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
Biopharmaceuticals
 HSMN NewsFeed - 6 Jul 2007
Dade Behring Introduces Innovance(TM) D-DIMER Test
Diagnostics
 HSMN NewsFeed - 30 Apr 2007
Humate-P(R) Approved to Prevent Excessive Bleeding in Patients with von Willebrand Disease Undergoing Surgery
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Feb 2007
Study Finds C1-Inhibitor Concentrate Is Safe and Effective in Treating Skin Swelling in Patients With Hereditary Angioedema
Biopharmaceuticals
 HSMN NewsFeed - 1 Feb 2007
CSL Behring and Bayer Extend Agreement for Supply of Helixate(R) Recombinant Coagulation Factor
Biopharmaceuticals Licensing Distribution
 HSMN NewsFeed - 1 Feb 2007
Grifols Announces FDA Approval of Alphanate(R) to Treat von Willebrand Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Jan 2007
CSL Behring Reports Progress on Global Implementation of Name Change
Biopharmaceuticals
 HSMN NewsFeed - 18 Dec 2006
ZLB Behring Completes Purchase of CytoGam(R) Immunoglobulin Therapy From MedImmune
Biopharmaceuticals Acquisitions
Return to NewsFeed  

 Additional items found! 2

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 2 additional stories matching:
von Willebrand Disease
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.